What are the causes of hyperkalemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Causes of Hyperkalemia

The most common causes of hyperkalemia are renal failure, medication effects (particularly renin-angiotensin-aldosterone system inhibitors), and cellular release of potassium, which can lead to potentially lethal cardiac arrhythmias and cardiac arrest. 1

Pathophysiological Classification of Hyperkalemia Causes

1. Decreased Potassium Excretion

  • Renal Failure

    • Acute kidney injury 1
    • Chronic kidney disease (risk increases as eGFR decreases, particularly <60 mL/min/1.73m²) 1
  • Medication-Induced 1, 2

    • Renin-angiotensin-aldosterone system inhibitors (RAASi):
      • ACE inhibitors
      • Angiotensin receptor blockers (ARBs)
      • Direct renin inhibitors (aliskiren)
      • Mineralocorticoid receptor antagonists (spironolactone, eplerenone)
    • Potassium-sparing diuretics (triamterene, amiloride)
    • NSAIDs
    • Beta-blockers
    • Calcineurin inhibitors (cyclosporine, tacrolimus)
    • Heparin and low molecular weight heparins
    • Trimethoprim-sulfamethoxazole
    • Pentamidine
    • Digitalis
  • Hypoaldosteronism 3

    • Primary adrenal insufficiency
    • Hyporeninemic hypoaldosteronism (common in diabetic nephropathy)

2. Transcellular Shift (Movement from Intracellular to Extracellular Space)

  • Acidosis - causes potassium to move out of cells 3
  • Insulin deficiency - reduces cellular potassium uptake 1
  • Tissue breakdown
    • Rhabdomyolysis
    • Tumor lysis syndrome
    • Hemolysis
    • Severe burns
    • Trauma
  • Medications causing cellular shift 2
    • Suxamethonium (depolarizing muscle relaxant)
    • Beta-blockers (non-selective)
    • Digoxin toxicity
    • Mannitol

3. Excessive Potassium Intake/Administration

  • Iatrogenic
    • IV potassium administration (especially in renal insufficiency) 1
    • Stored blood products transfusion 1
  • Dietary
    • Potassium supplements 4
    • Salt substitutes 1
    • High potassium foods (bananas, melons, orange juice) in patients with impaired excretion 1
  • Herbal/Alternative Products 1
    • Alfalfa
    • Dandelion
    • Hawthorne berry
    • Noni juice
    • Siberian ginseng

4. Pseudohyperkalemia

  • Hemolysis during blood collection 1
  • Thrombocytosis (>1,000/μL)
  • Leukocytosis (>100,000/μL)
  • Prolonged tourniquet use
  • Fist clenching during blood draw

High-Risk Populations

Certain patient populations have increased risk for hyperkalemia 1:

  • Advanced CKD (especially eGFR <15 mL/min/1.73m²)
  • Heart failure
  • Diabetes mellitus
  • Advanced age
  • Resistant hypertension
  • Recent myocardial infarction
  • Combination of the above conditions

Clinical Manifestations

Hyperkalemia may cause 1, 5:

  • Cardiac conduction abnormalities (peaked T waves, flattened P waves, widened QRS)
  • Muscle weakness
  • Flaccid paralysis
  • Paresthesias
  • Depressed deep tendon reflexes
  • Respiratory difficulties

Management Considerations

For severe hyperkalemia (>6.5 mmol/L) or with ECG changes, immediate treatment is required 1:

  1. Stabilize myocardial membrane: Calcium chloride or calcium gluconate
  2. Shift potassium into cells: Insulin with glucose, albuterol, sodium bicarbonate
  3. Enhance potassium elimination: Loop diuretics, potassium binders, dialysis

When hyperkalemia is medication-induced, consider dose adjustment or medication alternatives rather than complete discontinuation, especially with beneficial medications like RAASi 1.

Prevention Strategies

In high-risk patients:

  • Regular monitoring of serum potassium levels 1
  • Dietary counseling on potassium intake 5
  • Careful medication selection and dosing
  • Consider newer potassium binders (patiromer, sodium zirconium cyclosilicate) for chronic management in patients requiring RAASi therapy 1, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Drug-induced hyperkalemia.

Drug safety, 2014

Research

Pathogenesis, diagnosis and management of hyperkalemia.

Pediatric nephrology (Berlin, Germany), 2011

Research

Potassium Disorders: Hypokalemia and Hyperkalemia.

American family physician, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.